tirzepatide en polvo FDA confirms shortage is still over, gives compounders a grace period Tirzepatida liofilizada de alta pureza

Sobo, patients can discuss weight-loss goals in a clinical setting where the emphasis is on health, not hype

Hims & Hers raised its full-year 2026 revenue guidance to a range of $2.8 billion to $3 billion, representing growth of 19% to 28% from 2025 levels, and updated adjusted EBITDA guidance to a range of $275 million to $350 million.

You may need to take an oral rehydration solution to replace lost fluids and electrolytes

View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our view In 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry